Crystal structure of RIP1 kinase with a benzo[b][1,4]oxazepin-4-one

Experimental Data Snapshot

  • Resolution: 2.23 Å
  • R-Value Free: 0.248 
  • R-Value Work: 0.199 
  • R-Value Observed: 0.202 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.

Harris, P.A.King, B.W.Bandyopadhyay, D.Berger, S.B.Campobasso, N.Capriotti, C.A.Cox, J.A.Dare, L.Dong, X.Finger, J.N.Grady, L.C.Hoffman, S.J.Jeong, J.U.Kang, J.Kasparcova, V.Lakdawala, A.S.Lehr, R.McNulty, D.E.Nagilla, R.Ouellette, M.T.Pao, C.S.Rendina, A.R.Schaeffer, M.C.Summerfield, J.D.Swift, B.A.Totoritis, R.D.Ward, P.Zhang, A.Zhang, D.Marquis, R.W.Bertin, J.Gough, P.J.

(2016) J Med Chem 59: 2163-2178

  • DOI: https://doi.org/10.1021/acs.jmedchem.5b01898
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    The recent discovery of the role of receptor interacting protein 1 (RIP1) kinase in tumor necrosis factor (TNF)-mediated inflammation has led to its emergence as a highly promising target for the treatment of multiple inflammatory diseases. We screened RIP1 against GSK's DNA-encoded small-molecule libraries and identified a novel highly potent benzoxazepinone inhibitor series. We demonstrate that this template possesses complete monokinase selectivity for RIP1 plus unique species selectivity for primate versus nonprimate RIP1. We elucidate the conformation of RIP1 bound to this benzoxazepinone inhibitor driving its high kinase selectivity and design specific mutations in murine RIP1 to restore potency to levels similar to primate RIP1. This series differentiates itself from known RIP1 inhibitors in combining high potency and kinase selectivity with good pharmacokinetic profiles in rodents. The favorable developability profile of this benzoxazepinone template, as exemplified by compound 14 (GSK'481), makes it an excellent starting point for further optimization into a RIP1 clinical candidate.

  • Organizational Affiliation

    Platform Technology & Science, GlaxoSmithKline , Winter Street, Waltham, Massachusetts 02451, United States.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Receptor-interacting serine/threonine-protein kinase 1
A, B
303Homo sapiensMutation(s): 4 
Gene Names: RIPK1RIPRIP1
UniProt & NIH Common Fund Data Resources
Find proteins for Q13546 (Homo sapiens)
Explore Q13546 
Go to UniProtKB:  Q13546
PHAROS:  Q13546
GTEx:  ENSG00000137275 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ13546
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on 65U

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
C21 H19 N3 O4
Binding Affinity Annotations 
IDSourceBinding Affinity
65U BindingDB:  5HX6 Ki: 0.8 (nM) from 1 assay(s)
IC50: min: 1.6, max: 10 (nM) from 4 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.23 Å
  • R-Value Free: 0.248 
  • R-Value Work: 0.199 
  • R-Value Observed: 0.202 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 42.6α = 90
b = 101.35β = 90
c = 131.06γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
Aimlessdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2016-03-02
    Type: Initial release
  • Version 1.1: 2016-03-23
    Changes: Database references
  • Version 1.2: 2024-03-06
    Changes: Data collection, Database references, Derived calculations